Plasma and cellular Adriamycin concentrations in patients with myeloma treated with ninety‐six‐hour continuous infusion
Plasma and cellular Adriamycin concentrations in patients with myeloma treated with ninety‐six‐hour continuous infusion
复制标题
连续输注 96 小时的骨髓瘤患者的血浆和细胞阿霉素浓度
DOI：
--
复制
发表时间：
1987
期刊：
影响因子：
--
通讯作者：
C. Haanen
中科院分区：
文献类型：
--
作者：
P. Speth;P. Linssen;R. Holdrinet;C. Haanen
测定了7例晚期多发性骨髓瘤患者肿瘤浆细胞、有核血细胞、骨髓细胞和血浆中阿霉素（ADM）浓度。ADM以9 mg/m2/24 hr的剂量输注96小时，最大血浆ADM浓度为15.8 ± 4.4 ng/ml。在96小时输注期间，有核血细胞、骨髓细胞和浆细胞中的ADM浓度持续增加。最大细胞水平比最大血浆浓度高200倍，与一次快速注射总剂量给药后不久观察到的水平相似。96小时输注和推注的细胞AUC相当。因此，在将阿霉素输送到骨髓中的靶细胞方面，连续输注相当于推注，尽管血浆阿霉素浓度仍然非常低。这些结果为ADM连续输注给药提供了支持，毒性更小，患者耐受性更好。
Adriamycin (ADM) concentrations in neoplastic plasma cells, nucleated blood cells, bone marrow cells, and plasma were measured in seven patients with advanced multiple myeloma. ADM was administered as a 96‐hour infusion of 9 mg/m2/24 hr. Maximum plasma ADM concentrations were 15.8 ± 4.4 ng/ml. ADM concentrations in nucleated blood cells, bone marrow cells, and plasma cells increased continuously throughout the 96‐hour infusion. Maximum cellular levels were up to 200‐fold higher than the maximum plasma concentration and were similar to levels observed shortly after administration of the total dose in one rapid injection. The cellular AUC for 96‐hour infusion and bolus injection were comparable. Thus continuous infusion is the equivalent of bolus injection in delivering ADM to the target cells in bone marrow, although plasma ADM concentrations remained very low. These results provide support for administering ADM as a continuous infusion with less toxicity and better patient tolerance.
影响因子：
1.3
作者：
Kacperczyk-Bartnik, Joanna;Symonides, Aleksandra Helena;Derlatka, Pawel
通讯作者：
Derlatka, Pawel
影响因子：
158.5
作者：
BARLOGIE, B;SMITH, L;ALEXANIAN, R
通讯作者：
ALEXANIAN, R